Protocols involving continuous infusion therapy are widely recognized as the standard of care for treatment of advanced or metastatic colorectal cancer (CRC). And protocols have been approved for treatment of other cancer types including, anal cancer, biliary tract cancer, carcinoid tumor, cervical cancer, esophageal cancer, gastric cancer, head and neck cancer, leukemia, lymphoma, pancreatic cancer, and sarcoma.
In many cases, patients receiving continuous infusion therapy are treated using an ambulatory infusion pump. Ambulatory infusion provides patients greater freedom and mobility than continuous infusion delivered in an in-patient setting. Moreover, ambulatory infusion of chemotherapy is advantageous to payors, including managed care organizations, because it is generally less expensive than homecare or hospitalization and may help lower the costs incurred to treat the side-effects that may accompany traditional bolus treatment.
More than 60% of oncology practices across all 50 states use InfuSystem, and we are "in-network" in 160+ plans, covering over 125 million lives.
For patients, practices and payors, InfuSystem is ambulatory infusion made easy.